How long after someone has had herpes zoster (shingles) can they receive the Shingrix (recombinant zoster vaccine) vaccine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Timing of Shingrix Vaccination After Shingles

Individuals who have had shingles should wait at least 2 months after the acute episode has resolved before receiving the Shingrix vaccine. 1

Recommended Waiting Period

  • The 2-month minimum interval recommendation is based on documented evidence showing this is the minimum time between an episode of herpes zoster and potential recurrence 1
  • This waiting period allows for complete resolution of the acute phase of herpes zoster, abatement of symptoms, and recovery of the immune system to optimize vaccine response 1
  • Different countries have varying recommendations for the time frame between a shingles episode and vaccination:
    • USA and Germany: Wait until acute stage has resolved and symptoms have abated 1
    • Austria: Wait at least 2 months 1
    • Canada, Ireland, and Australia: Wait at least 1 year 1

Importance of Vaccination After Shingles

  • Having one episode of shingles does not provide reliable protection against future recurrences 2
  • A US study with 5.6 years of follow-up showed significant cumulative incidence of shingles recurrence: 2.5% at 2 years, 4.8% at 4 years, 6.6% at 6 years, 8.0% at 8 years, and 10.3% at 10 years 3, 1
  • Vaccination after a shingles outbreak is particularly important due to this high risk of recurrence 2

Vaccine Administration After Shingles

  • Shingrix (recombinant zoster vaccine, RZV) is the preferred vaccine for adults who have experienced a shingles outbreak due to its superior efficacy 1, 2
  • The vaccine should be administered as a 2-dose series with the second dose given 2-6 months after the first dose 2
  • For immunocompromised adults aged ≥18 years, a shorter schedule with the second dose given 1-2 months after the first dose may be considered 2
  • Shingrix maintains high efficacy across all age groups, with vaccine effectiveness of 97.2% in adults aged 50 years and older 2, 4
  • Real-world effectiveness studies show 70.1% effectiveness for 2 doses and 56.9% for 1 dose, highlighting the importance of completing the series 5

Special Considerations

  • Individuals who previously received the live zoster vaccine (Zostavax) can receive Shingrix at least 2 months after Zostavax 2, 6
  • For immunocompromised patients, Shingrix (which is a non-live vaccine) is the preferred option as it is considered safe, unlike the live Zostavax vaccine which is contraindicated in this population 2, 4
  • Vaccination rates show good uptake with approximately 70% of individuals completing the two-dose series within six months and 80% within 12 months of the initial dose 7

Clinical Pitfalls to Avoid

  • Waiting too long after the 2-month minimum period increases the risk of recurrence 1
  • Do not confuse the waiting period after shingles (minimum 2 months) with the interval between vaccine doses (2-6 months) 1, 2
  • Shingrix vaccination is not indicated to treat acute shingles or to prevent persons with acute shingles from developing postherpetic neuralgia 8
  • Do not miss the opportunity to vaccinate older adults who have had shingles, as they remain at significant risk for recurrence 1, 2

References

Guideline

Timing of Shingles Vaccination After a Shingles Outbreak

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

SHINGRIX Vaccination Schedule for Adults

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021

Research

Summary of the NACI Update on Herpes Zoster Vaccines.

Canada communicable disease report = Releve des maladies transmissibles au Canada, 2018

Research

Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).

MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.